Safety and Efficacy of EX103 in Subjects With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

Condition:   CD20-positive Non-Hodgkin Lymphoma Intervention:   Drug: EX103 injection Sponsor:   Guangzhou Excelmab Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials